Brokerages Expect Synlogic (SYBX) Will Announce Earnings of -$0.75 Per Share
Equities research analysts predict that Synlogic (NASDAQ:SYBX) will post ($0.75) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Synlogic’s earnings, with the lowest EPS estimate coming in at ($1.02) and the highest estimate coming in at ($0.62). Synlogic reported earnings of ($0.84) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.7%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Synlogic will report full-year earnings of ($2.98) per share for the current fiscal year, with EPS estimates ranging from ($3.88) to ($2.35). For the next financial year, analysts anticipate that the business will post earnings of ($3.09) per share, with EPS estimates ranging from ($3.96) to ($2.34). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Synlogic.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, March 20th. The biotechnology company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.07. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.11 million.
Several large investors have recently modified their holdings of the company. Artal Group S.A. bought a new position in shares of Synlogic in the 4th quarter worth approximately $5,335,000. Deutsche Bank AG lifted its stake in shares of Synlogic by 204.0% in the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 13,200 shares during the period. Renaissance Technologies LLC bought a new position in shares of Synlogic in the 4th quarter worth approximately $191,000. Finally, Spark Investment Management LLC bought a new position in shares of Synlogic in the 4th quarter worth approximately $105,000. Hedge funds and other institutional investors own 55.53% of the company’s stock.
Shares of SYBX stock opened at $11.38 on Thursday. Synlogic has a one year low of $8.76 and a one year high of $23.00. The stock has a market cap of $224.07, a P/E ratio of -1.94 and a beta of 2.21. The company has a current ratio of 9.82, a quick ratio of 9.82 and a debt-to-equity ratio of 0.01.
ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Synlogic (SYBX) Will Announce Earnings of -$0.75 Per Share” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/04/17/brokerages-expect-synlogic-sybx-will-announce-earnings-of-0-75-per-share.html.
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.